Insulin analogues with an acyl and alkylene glycol moiety
US9150633B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 15, 2008 |
| Grant date | Oct 6, 2015 |
| Priority date | — |
| Expiry date | Jan 27, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An acylated insulin analogue wherein the insulin analogue comprises a lysine residue connected C-terminally to the A21 amino acid residue or a peptide residue of up to 4 amino acid residues comprising a lysine residue which peptide residue is connected C-terminally to the A21 amino acid residue, characterized in that an acyl moiety comprising an alkylene glycol moiety is attached to the lysine residue in the A22 position or attached to a lysine residue present in the peptide residue that is attached to the C terminal end of the A21 amino acid residue and wherein there is only one lysine (K, Lys) in the insulin analogue, can conveniently be administered pulmonary.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.